CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

Post Marketing Surveillance of Oraquick Rapid HIV Testing Laura Wesolowski, PhD Gale R Burstein, MD, MPH Julia Zhu, MS Steven Ethridge, MT Division of.

Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

CLIA Waived Testing for Physician Office Labs Doris Thompson, Ph.D., MT (ASCP) AK State Public Health Laboratories State CLIA Program Francisca Lehr, M.S.,

MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.

Development of Guidance Documents Jennifer Scharpf, M. P. H

1 Quality System Considerations for Over-The-Counter HIV Testing Devery Howerton, Ph.D. Chief, Laboratory Practice Evaluation and Genomics Branch, Division.

CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.

Special Topics in IND Regulation

Quality Control Barbara Weberman MT(ASCP) Oakland County Health Division Laboratory Supervisor.

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.

CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.

HIV Screening and Women’s Health Health Care Education & Training, Inc. Originally developed by: Section 5: Test Options.

HIV Testing Quality Assurance and Quality Control

Rapid HIV Testing: 2003 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention.

CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.

FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.

CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.

Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.

Regulatory Update Ellen Leinfuss SVP, Life Sciences.

Regulatory Overview.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test 1 An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test OraSure Technologies, Inc.

HIV/AIDS is preventable and treatable, but is incurable.

1 OraQuick ® ADVANCE ™ HIV 1/2 Antibody Test (Oral Fluid Specimen Type) Blood Products Advisory Committee Meeting March 10, 2006.

RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.

Development of a detuned oral assay for recent HIV infection F. Priddy 1, P. Phelan 1, P. Tambe 1,2, C. del Rio 1 1 Emory University School of Medicine,

1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

Revision Process for the PHS Guideline for Reducing HIV, HBV and HCV Transmission through Solid Organ Transplantation Matthew J. Kuehnert, M.D. Office.

Regulatory Big Brother of Biotechnology. Role of FDA FDA was designed to promote and protect the public’s health Food and Drug Cosmetic Act first passed.

FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.

FDA’s Draft LDT Framework & Personalized Medicine Update

In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,

Approaches to Validation of Over-the- Counter (OTC) Home-Use HIV Test Kits Blood Products Advisory Committee November 3, 2005 Elliot P. Cowan, Ph.D. Chief,

Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.

Trinity Biotech Fingerstick whole blood sample for HIV OTC test Presented by; Fiona Campbell.

Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.

Introduction to the Clinical Laboratory

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.

Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.

Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.

Quality control & Statistics. Definition: it is the science of gathering, analyzing, interpreting and representing data. Example: introduction a new test.

Proposed Studies to Support the Approval of Over-the-Counter (OTC) Home-Use HIV Test Kits Blood Products Advisory Committee March 10, 2006 Elliot P. Cowan,

UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.

Regulatory Guidance for Genetic Testing. Three Specific Areas Laboratory tests Results of genetic testing – Clinical – Research GenomeWide Association.

Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

BioPlex 2200 HIV Ag-Ab Assay

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

15283 New Sensitive and Specific Rapid HSV-2 Antibody Test Objective To describe the performance and uses of a new HSV-2 specific serological rapid test,

Introduction to Quality Assurance. Quality assurance vs. Quality control.

IRB – Human subjects research incoming staff orientation 2017

Point of Care Testing California Clinical Laboratory Association

Unigold Recombigen HIV 1/2 Training for HIV Testing Sites

Updates COM Faculty Council

Quality System Considerations for Over-The-Counter HIV Testing

Quality Control Barbara Weberman MT(ASCP)

AIDS in the United States

A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING

About bioLytical Laboratories

Presentation transcript:

CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center for Biologics Evaluation and Research Food and Drug Administration Blood Products Advisory Committee Update March 13, 2003

Rapid HIV Test Approval u On November 7, 2002, FDA approved the OraQuick ® Rapid HIV-1 Antibody Test as a moderate complexity device under CLIA u Intended use: –To detect antibodies to HIV-1 in fingerstick whole blood specimens –A point-of-care test to aid in the diagnosis of infection with HIV-1 –Suitable for use in multi-test algorithms designed for statistical validation of rapid HIV test results

OraQuick ® is Approved as a Restricted Device u Sale is restricted to clinical laboratories –that have an adequate quality assurance program, including planned systematic activities to provide adequate confidence that requirements for quality will be met; and –where there is assurance that operators will receive and use the instructional materials u Approved for use only by an agent of a clinical laboratory

OraQuick ® Restrictions, cont. u Test subjects must receive the “Subject Information” pamphlet prior to specimen collection and appropriate information when test results are provided u Not approved for use to screen blood or tissue donors u Customer letter included with all kits –“By purchasing this device, you are doing so as an agent of a clinical laboratory and agree that you or any of your consignees will abide by the…restrictions on the sale, distribution, and use of the device…”

OraQuick ® Clinical Trial Data u Sensitivity in clinical trial: 99.6% (98.5%-99.9%) u Specificity in clinical trial: 100% (99.7%-100%)

OraQuick ® CLIA Waiver u OraQuick® was granted a CLIA waiver on January 31, 2003 u Data submitted in support of waiver –At 4 sites, 100 lay users with no laboratory experience tested panels of 6 masked randomized specimens »2 negative, 2 low positive, 2 high positive –No statistically significant difference between lay user results and correct results

OraQuick ® CLIA Waiver, cont. u Package insert for waived device in preparation –Will contain details on waiver studies u Sales and use restrictions remain in place for the waived test u Quality Assurance program recommendations for rapid HIV tests are being developed by CDC